1Mok CC, Tong KH, To CH, et al. Taerolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int,2005,68:813-817.
2Szeto CC, Kwan BC, Lai FM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) ,2008,47 : 1678-1681.
3Tanaka Y,Yamamoto K,Takeuchi T,et al. A muhicenter phase Ⅰ/Ⅱ trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol,2007,17 : 191-197.
4Tamimoto Y, Horiuchi T,Tsukamoto H, et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans'syndrome: immunological analysis of B cells,T cells and eytokines. Rheumatology ( Oxford ) ,2008,47:821-827.
5Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab ( anti- CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis,2007,66:470-475.
6Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody ) for immunolherapy of systemic lupus erythematosus. Arthritis Res Tber,2006,8 :R74.
7Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin Biol Ther,2008,8 : 1805-1814.
8Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther,2008, 10 : R109.
9Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator. Drugs R D ,2008,9 : 197-202.
10DallEra M, Chakravarty E, Wallace D, et at. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a muhicenter, phase Ib, double-blind, placebo-controlled, dose-escalating triM. Arthritis Rheum, 2007,56 : 41424150.
5Mak A, Cheung MW, Chiew HJ, et al.Global trend of sur- vival and damage of systemic lupus erythematosus: me- ta-analysis and meta-regression of observational studies from the 1950s to 2000s[J]. Semin Arthritis Rheum, 2012, 41(6):830.
